TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of midazolam boluses administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the International Prostate Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Adverse events/effects
Primary endpoint: Daily pain level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of Glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression of Glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in KOOS Knee Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paretic knee concentric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Beam-on time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Discontinuing Study Drug Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Cold pressor test response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Time in Range 70-180mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants with Marked Abnormalities in Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Vital sign Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional resonance imaging (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of TBI Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for TAK-954
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptoms measured by PCL-M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function improvement measured by CPFQ
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serologic response (≥4-fold HI titer rise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in score for symptoms and clinical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Binocular Photopic Uncorrected Intermediate Visual Acuity (UCIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of IC-8™ IOL Eyes Achieving Best-corrected Distance Visual Acuity (BCDVA) 0.3 logMAR or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of IC-8™ IOL Eyes With Cumulative Ocular Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of HES to prevent hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of seizures resulting in drops
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Performance on neuropsychological testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activation patterns measured by functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients Alive Without Disease Progression
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of amylase test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in midbrain and/or striatal SERT density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sdLDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum lipids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Treatment Response in Sleep Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of monoclonal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of CD25+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum inspiratory pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum expiratory pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Primary Fascial Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence rate to stroke secondary preventative medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants That Discontinued Study Medication Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: grades on final exams
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number and Percentage of Participants With Any Non-serious Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants With Solicited Systemic and Intestinal Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Major infection within 60 days
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma isoprostane level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum concentration of vascular endothelial growth factor A (VEGF-A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Cognitive and Affective Mindfulness Scale Revised
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on the Self Compassion Scale - Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: suppression of peak-stimulated Luteinizing Hormone (LH) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Probability of local complications
Endpoint domain: Adverse events/effects
Primary endpoint: Average Driving Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Thyroid Nodules
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in ENK Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of decompensating outpatients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the degree of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trough sitting systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of Venous Thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Glucose response measured by OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin response measured by OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass balance recovery of total radioactivity concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mass balance recovery of total radioactivity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mass balance recovery of total radioactivity in faecal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Opioid Consumption in MME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-vaccination Geometric Mean Titer Against Influenza Virus A/H1N1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination Geometric Mean Titer Against Egg-grown Influenza Virus A/H3N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination GMT Against Cell-grown Influenza Virus A/H3N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination Geometric Mean Titer Against Influenza B(Victoria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination Geometric Mean Titer Against Influenza B(Yamagata)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients treated successfully for pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume and diffusion parameters in gray matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of Motor and Sensory Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance on a social cognition test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Eyetracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of biological samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Number of Drinking Days Per Week
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Anti-proliferative effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rated intensity profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Joint cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in brain function (functional connectivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decline in NIH-CPSI Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to Dementia
Endpoint domain: Mortality/survival
Primary endpoint: Type of Dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Assessment of Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bone mineral density at the total lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lyshom Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tegner-activity scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS Pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean insulin secretion output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of Atorvastatin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Therapeutic Cure at 42 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type and incidence of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of treatment related adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cytokine release syndrome (CRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Immune effector cell-associated neurotoxicity syndrome (ICANS)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of Non-Relapse Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients completing therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Galantamine PK parameters (Cmax, Tmax, AUC(TAU), Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Hoehn and Yahr Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ of AJU-A51R1 and AJU-A51R2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,max of AJU-A51R1 and AJU-A51R2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Habits Confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exercise Confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Knowledge of Cardiovascular Disease Risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Control Over Cardiovascular Disease Risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Asthma Control Questionnaire (ACQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference of vertical distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean 2-hour AUC for plasma c-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Favourable healing outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of telaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum plasma concentration (Cmin) of telaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of telaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of surgical target in removed specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clearing of signs and symptoms of contact dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-reported pain-free function domain score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patients wanting to take part in decision making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients choosing the lower radiation dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vascular Permeability (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative Cerebral Blood Volume (rCBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Participants Predicted Within 20% of Their Actual Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection rate in colorectal surgeries
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in treatment of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success rate of core needle biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of GI Clinic Capacity Filled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Renal Artery Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum tolerated dose of dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Testosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dihydrotestosterone (DHT) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Aesthetic improvement using POSAS scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Aesthetic improvement using ASAS scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Continuous Quit Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of High Altitude Pulmonary Edema (HAPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevention of tobacco use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage total body weight loss (%TBWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (Hour*ng/mL) Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (ng/mL) Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kel (Hour^-1) Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of program offerings implemented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional HIV cure in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients experiencing grade 3/4 acute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: 2-years disease-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With >=1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With >= 1 Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour IOP pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Inter-practician variability of clinical care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Duration of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: F-18 RDG-K5 Uptake by Carotid Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute safety event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of the index ablation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Lost Productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: oocyte retrieved number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: D-wave measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical motor status according to the MRC scheme
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Constipation Severity Scale (CSS) average score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection rate of clinically significant prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of trial on improving stress coping ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effectiveness of trial on improving resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Electromagnetic oversensing
Endpoint domain: Adverse events/effects
Primary endpoint: Binocular best-corrected visual acuity in Snellen equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from composite endpoint of death, index limb amputation, and target vessel revascularization (TVR)
Endpoint domain: Mortality/survival
Primary endpoint: Gene Mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of obesity in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 year predicted cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: [18F]FDG uptake in brown adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Motor Evoked Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Antiplaque efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes